Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices

President Donald Trump on Thursday announced deals with obesity drug makers Eli Lilly and Novo Nordisk to cut prices on their GLP-1 drugs in return for a three-year U.S. tariff reprieve.

“It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump said at a White House event.

TrumpRx Prices

Under the deal, the prices of injectable Ozempic and Wegovy will fall to $350 when purchased through TrumpRx. TrumpRx is a platform slated for launch by the administration in January 2026, offering medicines directly to consumers.

Initial doses of oral GLP-1 weight-loss drugs will be priced at $150 per month through the platform. Both Lilly and Novo expect to launch their oral obesity drugs next year.

Other Lilly and Novo drugs will also be available at a discount under the deals through TrumpRx, including Lilly’s migraine treatment, Emgality, and Novo’s insulin products, such as NovoLog and Tresiba.

Medicare Coverage

Medicare, the government health plan for older people, and Medicaid, the insurance program for low-income and disabled people, will now cover obesity drugs for adults. Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245 under the deal. The co-pay for Medicare patients will be $50 per month.

Medicare previously didn’t cover weight-loss drugs.

However, Trump's announcement on Thursday was cut short after a company representative fainted.

Trump has already inked similar deals with drugmakers including Pfizer, AstraZeneca, and Merck. The President sent a letter to 17 drugmakers, including Lilly and Novo, earlier this year, insisting that they cut drug prices in the U.S. to levels paid by other developed countries.

While LLY shares traded flat at the time of writing, NVO shares dropped 3%. 

Also See: Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on